News
February 16, 2022 – Current Report No. 4/2022 – The KDPW statement on concluding an agreement on the registration of the Company’s series C shares
Legal basis: Article 56 section 1 point 2 Act on Public Offering – current and periodic information.Date: February 16, 2022.The abbreviated name of the issuer CELON PHARMA S.A.Subject: The KDPW statement on concluding an agreement on the registration of the Company’s series C shares The Management Board of Celon Pharma SA (the “Company”) hereby informsRead more »
January 21, 2022 – Current Report No. 3/2022 – Phase II clinical trial of CPL’280 in treatment of type 2 diabetes commenced
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Date: January 21, 2022, time: 05:08 p.m. The Management Board of Celon Pharma S.A. (“Company”) announces that on January 21, 2022, it learned about the inclusion of the first patient in the Phase II clinical trial of CPL’280, a second-generationRead more »
The results of CPL’36 – PDE10a inhibitor to be presented in the poster session at Neuroscience 2021.
This year, from November 8-11, the jubilee, 50th edition of the conference organized by the Society for Neuroscience – the world’s largest organization of scientists and doctors dealing with brain diseases will take place. Despite the fact that the event is planned in the online formula, the organizers have planned numerous lectures, poster sessions andRead more »
Celon Pharma S.A. at the Jefferies Healthcare Conference 2021.
Representatives of the Management Board of Celon Pharma S.A. will take part in the 12th edition of the largest European conference on life science.
3 posters to be published at 34th ECNP Congress
The 34th ECNP Congress will take place on October 2-5 in Lisbon. This is the most important European scientific meeting dedicated to brain research for disease. Each year, this event attracts over 5,000 psychiatrists, neurologists and psychologists from around the world. During the 34th ECNP Congress, posters will be presented. Posters by Sylwia Janowska –Read more »
Celon Pharma at EASD 2021
The EASD Annual Meeting is one of the largest scientific congresses, presenting the latest results from basic and clinical diabetes research and the place to meet the global diabetes community.
Celon Pharma Capital Markets Day – 21.04.2021
Capital Markets Day to be held on Wednesday, April 21, 2021 at 10:00 AM ET / 16:00 Warsaw Time Zone. Join Corporate and KOL’s session. Prof. Eduard Vieta Chair at the University of Barcelona and Head of the Department of Psychiatry and Psychology at the Hospital Clinic and Prof. Jair C. Soares, MD, PhD –Read more »
Celon Pharma in the Stock Exchange Company of the Year ranking
Celon Pharma took 2nd place in the Development prospects category in the 22nd edition of the Stock Exchange Company of the Year 2020. The GSR report was prepared on the basis of an assessment of companies in the course of a special online survey in which companies & nbsp; to be assessed in accordance withRead more »
Celon Pharma at Top Picks by Trigon Investor Conference
On January 21, 2021, representatives of the Company’s Management Board will take part in the Top Picks by Trigon conference. Celon Pharma was among 21 companies recommended by Trigon DM in 2021.